Literature DB >> 26689942

'As required' medication regimens for seriously mentally ill people in hospital.

Petrina Douglas-Hall1, Emma V Whicher.   

Abstract

BACKGROUND: Drugs used to treat psychotic illnesses may take weeks to be effective. In the interim, additional 'as required' doses of medication can be used to calm patients in psychiatric wards. The practice is widespread, with 20% to 50% of people on acute psychiatric wards receiving at least one 'as required' dose of psychotropic medication during their admission.
OBJECTIVES: To compare the effects of 'as required' medication regimens with regular patterns of medication for the treatment of psychotic symptoms or behavioural disturbance, thought to be secondary to psychotic illness. These regimens may be given alone or in addition to any regular psychotropic medication for the long-term treatment of schizophrenia or schizophrenia-like illnesses. SEARCH
METHODS: We searched the Cochrane Schizophrenia Group's Trials Register, which is based on regular searches of MEDLINE, EMBASE, PubMed, CINAHL, BIOSIS, AMED, PsycINFO and registries of clinical trials, in November 2001, March 2006, July 2012 andOctober 2013. SELECTION CRITERIA: We aimed to include all relevant randomised controlled trials involving hospital inpatients with schizophrenia or schizophrenia-like illnesses, comparing any regimen of medication administered for the short-term relief of behavioural disturbance, or psychotic symptoms, to be given at the discretion of ward staff ('as required', 'prn') with fixed non-discretionary patterns of drug administration of the same drug(s). This was in addition to regular psychotropic medication for the long-term treatment of schizophrenia or schizophrenia-like illnesses where prescribed. DATA COLLECTION AND ANALYSIS: We independently inspected abstracts and papers for inclusion. If trials had been found, we would have extracted data from the papers and quality assessed the data. For dichotomous data we would have calculated the risk ratios (RR), with the 95% confidence intervals (CI). We would have conducted analyses on an intention-to-treat basis. If data were available we would have completed a 'Summary of findings' table using GRADE. MAIN
RESULTS: We have not been able to identify any randomised trials comparing 'as required' medication regimens to regular regimens of the same drug. Our main outcomes of interest were important changes in (i) mental state, (ii) behaviour, (iii) dose of medication used, (iv) adverse events, (v) satisfaction with care and (iv) cost of care. AUTHORS'
CONCLUSIONS: There is currently no evidence from within randomised trials to support this common practice. Current practice is based on clinical experience and habit rather than high quality evidence.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26689942      PMCID: PMC7052742          DOI: 10.1002/14651858.CD003441.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  48 in total

Review 1.  Systematic reviews in health care: Assessing the quality of controlled clinical trials.

Authors:  P Jüni; D G Altman; M Egger
Journal:  BMJ       Date:  2001-07-07

2.  Issues in the meta-analysis of cluster randomized trials.

Authors:  Allan Donner; Neil Klar
Journal:  Stat Med       Date:  2002-10-15       Impact factor: 2.373

3.  Imputing missing standard deviations in meta-analyses can provide accurate results.

Authors:  Toshi A Furukawa; Corrado Barbui; Andrea Cipriani; Paolo Brambilla; Norio Watanabe
Journal:  J Clin Epidemiol       Date:  2006-01       Impact factor: 6.437

4.  [The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use].

Authors:  J P Boissel; M Cucherat; W Li; G Chatellier; F Gueyffier; M Buyse; F Boutitie; P Nony; M Haugh; G Mignot
Journal:  Therapie       Date:  1999 Jul Aug       Impact factor: 2.070

Review 5.  Risperidone versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Sandra Schwarz; Franziska Schmid; Heike Hunger; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

6.  Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia.

Authors:  Bruce J Kinon; Jonna Ahl; Matthew D Rotelli; Edmund McMullen
Journal:  Am J Emerg Med       Date:  2004-05       Impact factor: 2.469

7.  Sodium cromoglycate eye drops: regular versus "as needed" use in the treatment of seasonal allergic conjunctivitis.

Authors:  E F Juniper; G H Guyatt; P J Ferrie; D R King
Journal:  J Allergy Clin Immunol       Date:  1994-07       Impact factor: 10.793

Review 8.  'As required' medication regimens for seriously mentally ill people in hospital.

Authors:  A Chakrabarti; E Whicher; M Morrison; P Douglas-Hall
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

Review 9.  Quetiapine versus other atypical antipsychotics for schizophrenia.

Authors:  Laila Asmal; Srnka J Flegar; Jikun Wang; Christine Rummel-Kluge; Katja Komossa; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2013-11-18

Review 10.  Haloperidol versus chlorpromazine for schizophrenia.

Authors:  C Leucht; M Kitzmantel; L Chua; J Kane; S Leucht
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23
View more
  7 in total

Review 1.  Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).

Authors:  Edoardo G Ostinelli; Melanie J Brooke-Powney; Xue Li; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2017-07-31

Review 2.  Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).

Authors:  Edoardo G Ostinelli; Salwan Jajawi; Styliani Spyridi; Kamlaj Sayal; Mahesh B Jayaram
Journal:  Cochrane Database Syst Rev       Date:  2018-01-08

Review 3.  Patient Safety and Pro Re Nata Prescription and Administration: A Systematic Review.

Authors:  Mojtaba Vaismoradi; Sara Amaniyan; Sue Jordan
Journal:  Pharmacy (Basel)       Date:  2018-08-29

4.  Managing acutely aggressive or agitated people in a psychiatric setting: a survey in Lebanon.

Authors:  Joseph E Dib; Clive E Adams; Francois Kazour; Fouad Tahan; Georges Haddad; Chadia Haddad; Souheil Hallit
Journal:  Med J Islam Repub Iran       Date:  2018-07-15

5.  The pharmacological management of acute behavioural disturbance: Data from a clinical audit conducted in UK mental health services.

Authors:  Carol Paton; Clive E Adams; Stephen Dye; Elizabeth Fagan; Chike Okocha; Thomas Re Barnes
Journal:  J Psychopharmacol       Date:  2018-12-19       Impact factor: 4.153

Review 6.  PRN Medicines Management for Psychotropic Medicines in Long-Term Care Settings: A Systematic Review.

Authors:  Mojtaba Vaismoradi; Flores Vizcaya Moreno; Hege Sletvold; Sue Jordan
Journal:  Pharmacy (Basel)       Date:  2019-11-25

7.  Practical Considerations of PRN Medicines Management: An Integrative Systematic Review.

Authors:  Abbas Mardani; Piret Paal; Christiane Weck; Shazia Jamshed; Mojtaba Vaismoradi
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.